🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Marksans Pharma Limited MARKSANS NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://marksanspharma.com

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

READ MORE ›
₹246.19
-5.06% 1Y

Market & Price

Market Cap
₹11,156.44 Cr
Current Price
₹246.19
High / Low (52W)
₹262.62 / ₹156.89
Beta
0.98

Valuation

Stock P/E
26.67
Industry PE
37.60
Forward P/E
18.24
PEG Ratio
1.12
Book Value
₹59.37
Price to Book
4.15
P/S
3.78
EV/EBITDA
17.54
Dividend Yield
0.32%

Profitability & Returns

ROCE
17.54%
ROE
15.16%
ROA
8.84%
Profit Margin
14.16%
Op Margin
19.99%
EPS (Latest Qtr)
₹3.27
EPS (TTM)
₹9.23

Balance Sheet & Liquidity

Debt/Equity
0.11
Quick Ratio
3.12
Current Ratio
5.17
Debt
₹343.38 Cr
Total Assets
₹3,860.90 Cr
Current Assets
₹2,722.74 Cr
Working Capital
₹2,195.65 Cr

Ownership

Promoter Holding
44.06%
Chg in Prom Hold
-
FII / Inst Holding
18.50%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹10,535.51 Cr
Total Revenue (TTM)
₹2,950.94 Cr
EBITDA
₹600.78 Cr
Free Cash Flow
₹70.35 Cr
Operating Cash Flow
₹458.13 Cr
Shares Outstanding
₹45.32 Cr
Gross Margin
56.72%
Payout Ratio
8.68%

Growth (CAGR)

Revenue 5Y
16.85%
Profit 5Y
16.21%
Revenue (YoY)
20.80%
Earnings (YoY)
63.50%

PROS

  • Compounding revenue at 16.8% over 5 years.
  • Profit CAGR of 16.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MARKSANS Marksans Pharma Limited NSEPHARMA 246.19 26.67 ₹11,156.44 Cr 0.32% 17.54% 15.16% 16.85% 16.21%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -681.85 Cr708.46 Cr619.99 Cr720.41 Cr754.43 Cr856.11 Cr
Cost of Revenue -298.54 Cr325.22 Cr261.81 Cr308.59 Cr316.22 Cr390.65 Cr
Gross Profit -383.30 Cr383.24 Cr358.18 Cr411.82 Cr438.20 Cr465.46 Cr
Operating Expenses -273.59 Cr279.05 Cr281.15 Cr294.24 Cr301.79 Cr294.33 Cr
Operating Income -109.71 Cr104.19 Cr77.02 Cr117.58 Cr136.41 Cr171.13 Cr
EBITDA -166.41 Cr142.27 Cr105.76 Cr166.06 Cr180.89 Cr230.59 Cr
Interest Expense -2.57 Cr3.44 Cr6.07 Cr5.82 Cr5.93 Cr6.31 Cr
Pretax Income -143.26 Cr116.09 Cr76.60 Cr133.33 Cr150.62 Cr200.00 Cr
Tax Provision -38.19 Cr25.37 Cr18.40 Cr34.20 Cr36.93 Cr50.97 Cr
Net Income -104.56 Cr90.55 Cr58.32 Cr98.25 Cr113.20 Cr148.13 Cr
Diluted EPS 2.132.312.001.292.172.503.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,849.62 Cr2,174.20 Cr2,622.84 Cr2,950.94 Cr
Cost of Revenue -958.08 Cr1,096.95 Cr1,143.74 Cr1,277.28 Cr
Gross Profit -891.54 Cr1,077.24 Cr1,479.10 Cr1,673.66 Cr
Operating Expenses -578.64 Cr689.75 Cr1,029.81 Cr1,171.51 Cr
Operating Income -312.90 Cr387.50 Cr449.30 Cr502.15 Cr
EBITDA -395.25 Cr509.00 Cr599.01 Cr683.31 Cr
Interest Expense -5.75 Cr11.20 Cr11.66 Cr24.12 Cr
Pretax Income -337.65 Cr423.53 Cr503.97 Cr560.55 Cr
Tax Provision -72.33 Cr108.63 Cr121.35 Cr140.49 Cr
Net Income -266.31 Cr313.70 Cr380.57 Cr417.90 Cr
Diluted EPS -6.416.928.409.22

Compounded Sales Growth

5 Years:16.85%
1 Year:20.80%

Compounded Profit Growth

5 Years:16.21%
1 Year:63.50%

Stock Price Performance

1 Year:-5.06%
6 Months:+30.57%
3 Months:+41.43%
1 Month:+33.34%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,190.39 Cr2,680.95 Cr3,239.63 Cr3,860.90 Cr
Current Assets -1,675.30 Cr1,862.49 Cr2,204.12 Cr2,722.74 Cr
Cash & Equivalents -382.44 Cr403.28 Cr495.79 Cr634.14 Cr
Inventory -484.74 Cr617.94 Cr845.52 Cr972.28 Cr
Receivables -416.85 Cr453.18 Cr540.04 Cr644.57 Cr
Total Liabilities -425.32 Cr595.05 Cr750.25 Cr808.22 Cr
Current Liabilities -340.99 Cr389.85 Cr477.34 Cr527.09 Cr
Long Term Debt 0----
Total Debt -122.94 Cr244.06 Cr321.91 Cr343.38 Cr
Total Equity -1,745.16 Cr2,065.05 Cr2,466.91 Cr3,023.16 Cr
Shares Outstanding -45.32 Cr45.32 Cr45.32 Cr45.32 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -237.41 Cr230.41 Cr206.66 Cr458.12 Cr
Investing Cash Flow --259.21 Cr-140.84 Cr-49.01 Cr-248.27 Cr
Financing Cash Flow -197.83 Cr-68.73 Cr-65.15 Cr-70.93 Cr
Capital Expenditure --53.63 Cr-208.84 Cr-172.92 Cr-130.53 Cr
Free Cash Flow -183.78 Cr21.57 Cr33.74 Cr327.60 Cr
Net Change in Cash -176.03 Cr20.84 Cr92.51 Cr138.93 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -48.2%49.5%56.4%56.7%
Operating Margin % -16.9%17.8%17.1%17.0%
Net Margin % -14.4%14.4%14.5%14.2%
ROE % -15.3%15.2%15.4%13.8%
ROCE % -16.9%16.9%16.3%15.1%

Shareholding Pattern

Insiders
44.06%
Institutions
18.50%
Public Float
33.07%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MARKSANS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space